Evaluation of a maleimido derivative of CHX-A'' DTPA for site-specific labeling of affibody molecules.
暂无分享,去创建一个
M. Brechbiel | L. Abrahmsén | V. Tolmachev | A. Orlova | M. Sandström | S. Ahlgren | A. Sjöberg | Heng-Wei Xu | M. Hjertman | H. Wållberg | H. Wållberg
[1] Jinha M. Park,et al. 64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors , 2010, Molecular Imaging and Biology.
[2] Vladimir Tolmachev,et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[3] A. Buzdar,et al. Evolving novel anti-HER2 strategies. , 2009, The Lancet. Oncology.
[4] Joachim Feldwisch,et al. Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine , 2009, Journal of Nuclear Medicine.
[5] D. Mankoff. Molecular imaging to select cancer therapy and evaluate treatment response. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[6] Stefan Ståhl,et al. Engineered affinity proteins--generation and applications. , 2009, Journal of biotechnology.
[7] J. Sutcliffe,et al. Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A Chelates for Targeted Positron Emission Tomography with an αvβ6-Specific Peptide , 2009 .
[8] S. Stone-Elander,et al. On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model , 2009, Journal of Nuclear Medicine.
[9] A. Orlova,et al. Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors , 2009, Molecular Imaging and Biology.
[10] V. Tolmachev,et al. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Fan Wang,et al. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[12] V. Tolmachev. Imaging of HER-2 overexpression in tumors for guiding therapy. , 2008, Current pharmaceutical design.
[13] A. Orlova,et al. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. , 2008, Cancer biotherapy & radiopharmaceuticals.
[14] T. Wadas,et al. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[15] S. Gambhir,et al. Direct Site-Specific Radiolabeling of an Affibody Protein with 4-[18F]Fluorobenzaldehyde via Oxime Chemistry , 2008, Molecular Imaging and Biology.
[16] Young Joo Kim,et al. Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)–Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice , 2008, Journal of Nuclear Medicine.
[17] M. Brechbiel,et al. A novel bifunctional maleimido CHX-A'' chelator for conjugation to thiol-containing biomolecules. , 2008, Bioorganic & medicinal chemistry letters.
[18] Luis M. De Leon-Rodriguez,et al. The synthesis and chelation chemistry of DOTA-peptide conjugates. , 2008, Bioconjugate chemistry.
[19] B. Långström,et al. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. , 2008, Bioconjugate chemistry.
[20] J. Feldwisch,et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. , 2008, Bioconjugate chemistry.
[21] L. Martiniova,et al. [18F]FBEM-ZHER2:342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[22] Joachim Feldwisch,et al. Update: affibody molecules for molecular imaging and therapy for cancer. , 2007, Cancer biotherapy & radiopharmaceuticals.
[23] A. Karlström,et al. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. , 2007, Bioconjugate chemistry.
[24] S. Deutscher,et al. Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor–Expressing Breast Carcinomas , 2007, Clinical Cancer Research.
[25] A. Scott,et al. Radioimmunotherapy with α-Particle–Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy , 2007, Clinical Cancer Research.
[26] V. Tolmachev,et al. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. , 2007, International journal of molecular medicine.
[27] Hjalmar Brismar,et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. , 2007, Nuclear medicine and biology.
[28] Timothy J. Hoffman,et al. In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems , 2007, Journal of Nuclear Medicine.
[29] S. Figueroa,et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues , 2007, Proceedings of the National Academy of Sciences.
[30] A. Karlström,et al. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[31] H. Brismar,et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. , 2007, Protein engineering, design & selection : PEDS.
[32] L. Abrahmsén,et al. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy , 2007, Expert opinion on biological therapy.
[33] Vladimir Tolmachev,et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. , 2007, Cancer research.
[34] A. Bruskin,et al. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. , 2007, Bioconjugate chemistry.
[35] R. Pehrson,et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. , 2007, Cancer research.
[36] V. Tolmachev,et al. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. , 2007, Current opinion in drug discovery & development.
[37] V. Tolmachev,et al. Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. , 2007, International journal of molecular medicine.
[38] E. Lundberg,et al. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. , 2007, Journal of immunological methods.
[39] A. Bruskin,et al. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[40] Peter A Kaufman,et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Brechbiel,et al. Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide. , 2006, Journal of medicinal chemistry.
[42] Vladimir Tolmachev,et al. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[43] J. Carlsson,et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.
[44] J. Carlsson,et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] M. Duffy,et al. Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations , 2005, Tumor Biology.
[46] V. Tolmachev,et al. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. , 2005, Bioconjugate chemistry.
[47] M. Brechbiel,et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. , 2005, Cancer biotherapy & radiopharmaceuticals.
[48] A. Scott,et al. Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A″-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478 , 2005, Clinical Cancer Research.
[49] Vladimir Tolmachev,et al. [177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[50] H. Klocker,et al. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. , 2005, Cancer research.
[51] David C. Smith,et al. Advances in Prostate Cancer Chemotherapy: A New Era Begins 1 , 2005, CA: a cancer journal for clinicians.
[52] K. Wester,et al. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases , 2005, BJU international.
[53] J. Mohler,et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. , 2005, Cancer research.
[54] Giovanni Paganelli,et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[55] M. Brechbiel,et al. Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease , 2004, Clinical Cancer Research.
[56] M. Brechbiel,et al. A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice , 2004, Cancer Research.
[57] E. Crawford,et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial , 2004, The Prostate.
[58] K. Wester,et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review , 2004, British Journal of Cancer.
[59] J. Doroshow,et al. Trastuzumab plus docetaxel in HER‐2/neu‐positive prostate carcinoma , 2004, Cancer.
[60] J. Reubi. Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.
[61] L. Chappell,et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. , 2002, Nuclear medicine and biology.
[62] J. Reubi,et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. , 2002, Bioconjugate chemistry.
[63] R. Valkema,et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.
[64] A. Becker,et al. Trastuzumab and breast cancer. , 2001, The New England journal of medicine.
[65] T. Waldmann,et al. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. , 2000, Journal of the National Cancer Institute.
[66] T. Waldmann,et al. Anti-HER2 radioimmunotherapy. , 2000, Breast Disease.
[67] S. Mather,et al. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[68] Y. Bignon,et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). , 2000, International journal of oncology.
[69] C. Cordon-Cardo,et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. , 2000, Cancer research.
[70] C. Cordon-Cardo,et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. , 1999, Cancer research.
[71] D. Scheinberg,et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[72] E. Krenning,et al. Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. , 1999, Proceedings of the Association of American Physicians.
[73] E P Krenning,et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. , 1998, Cancer research.
[74] G. Griffiths,et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[75] Arthur E. Martell,et al. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles , 1991 .
[76] A. Martell,et al. STABILITIES OF THE FE(III), GA(III) AND IN(III) CHELATES OF N,N',N''-TRIAZACYCLONONANETRIACETIC ACID , 1991 .
[77] H. Adams,et al. Crystal and molecular structure of a seven-coordinate chloroindium(III) complex of 1,4,7-triazacyclononanetriacetic acid , 1989 .